Decision about enzalutamide in chemo-naive mCRPC


According to a joint media release, issued yesterday by Medivation and Astellas, the U.S. Food & Drug Administration (FDA) has granted a priority review for the supplementary New Drug Application (sNDA) for the use of enzalutamide in the treatment of chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC).

This priority review means that the FDA will make a decision on or before September 18, 2014 — based on data from the PREVAIL trial — regarding approval of the use of enzalutamide in patients with chemotherapy-naive mCRPC. The “New” Prostate Cancer InfoLink expects this decision to be favorable for the companies (and for patients), and it may well come significantly earlier than mid-September.

One Response

  1. Good. We need it approved.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: